Schwarz Pharma Reports Progress of Parkinson's Patch
Posted on: Thursday, 4 January 2007, 12:00 CST
German pharmaceutical company Schwarz Pharma has reported positive results for its early-stage Parkinson's disease skin patch in phase III trials.
The study, designed to evaluate the safety and efficacy of the once-daily dopamine agonist rotigotine, found that the drug significantly improved symptoms in the patients taking part versus placebo. In addition, rotigotine appeared to be well-tolerated by patients.
Lead investigator Ray Watts, director of clinical research and chairman of neurology at the University of Alabama, said: "Parkinson's disease is a progressive disorder and this important study showed that rotigotine may be safe and effective, and potentially be of significant value in the treatment of early-stage PD.
"Rotigotine is a dopamine agonist that offers continuous drug delivery with a once-daily patch, which will hopefully mitigate the practical intra-day variability that accompanies the multiple dose regimens of other dopaminergic drugs."
Rotigotine is designed to mimic the action of dopamine, a naturally-produced neurotransmitter crucial for proper motor functioning. Parkinson's disease patients primarily suffer from a lack of dopamine which affects movement coordination.
Source: Datamonitor
Related Articles
- Only 44.4 Percent of Parkinson's Disease Patients Receive Drug Treatment Within One Year of Being Diagnosed
- Sixty-One Percent of Newly Diagnosed Parkinson's Disease Patients Do Not Receive Any Drug Treatment in the First Year of Diagnosis
- FDA Approves SCHWARZ PHARMA's Neupro(R) (Rotigotine Transdermal System) for the Treatment of Early-Stage Parkinson's Disease in USA
- SCHWARZ PHARMA Announces Publication of Rotigotine Data for Advanced Parkinson's Disease in Neurology
- One of the Largest-Ever Parkinson's Disease Studies Initiated Across the United States
- ACADIA Pharmaceuticals Announces Positive Results From Phase II Trial of ACP-103 for Treatment-Induced Psychosis in Patients With Parkinson's Disease
- Ceregene Reports Initiation of Phase 1 Clinical Trial of Novel Gene Therapy for Patients With Parkinson's Disease
- Avigen Announces Encouraging Early Data From Parkinson's Disease Clinical Trial
- Neuroleptic Malignant Syndrome in a Patient With Parkinson's Disease: A Case Study
- Striatal Dopamine Transporter Imaging Correlates With Anxiety and Depression Symptoms in Parkinson's Disease
 |
 |
User Comments (0)
RSS Feeds